Purification of a Specific Placental Plasminogen Activator Inhibitor by Monoclonal Antibody and Its Complex Formation with Plasminogen Activator

No abstract is available for this paper.

• Publication year

  1985

• Venue

  Thrombosis and Haemostasis

• Publication date

  1985-02-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1055/s-0038-1661250PMID 3922076
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differential inhibition of two molecular forms of melanoma cell plasminogen activator by a placental inhibitor

  1984cited by this paper
• Kinetics of the Reaction Between Urokinase and an Inhibitor of Fibrinolysis from Placental Tissue

  1982cited by this paper
• Immunoradiometric quantification of tissue plasminogen activator secreted by fetal organs. Comparison with urokinase.

  1982cited by this paper
• Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture.

  1981cited by this paper
• Radioimmunoassay of urokinase for quantification of plasminogen activators released in ovarian tumour cultures.

  1981cited by this paper
• Production of monoclonal antibodies: strategy and tactics.

  1980cited by this paper
• The isolation of hybrid cell lines producing monoclonal antibodies against the p15(E) protein of ecotropic murine leukemia viruses.

  1979cited by this paper
• An inhibitor from placenta specifically binds urokinase and inhibits plasminogen activator released from ovarian carcinoma in tissue culture.

  1978cited by this paper
• Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose.

  1978cited by this paper
• Purification of urokinase by affinity chromatography.

  1976cited by this paper
• On the proteolytic inhibitory effect of human foetal and neoplastic tissues.

  1976cited by this paper
• Fibrinolysis associated with oncogenic transformation. Partial purification and characterization of the cell factor, a plasminogen activator.

  1974cited by this paper
• Histochemical study of an inhibitor of fibrinolysis in the human arterial wall

  1974cited by this paper
• Enzyme-linked immunosorbent assay, Elisa. 3. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes.

  1972cited by this paper
• Inhibitory Effect of Placenta on Plasminogen Activation in Human Organ Culture 1

  1972cited by this paper
• Inhibition of plasminogen activators by naturally occurring inhibitors in man.

  1972cited by this paper
• Studies on Fibrinolytic Inhibitors During Pregnancy

  1971cited by this paper
• The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.

  1969cited by this paper
• Urokinase Inhibitor in Human Placenta

  1968cited by this paper
• Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.

  1966cited by this paper
• The fibrin plate method for estimating fibrinolytic activity.

  1952cited by this paper

• Physiology of Haemostasis: Plasmin-Antiplasmin System

  2020cites this paper
• PLASMINOGEN ACTIVITY AND INHIBITORS IN NORMAL LATE PREGNANCY POSTPARTUM AND IN THE POSTNATAL PERIOD

  2019cites this paper
• A SerpinB2 és a SerpinB10 szerepe a DNS hibajavításban és a tumoros folyamatokban

  2019cites this paper
• Plasminogen activator activity in tears of pregnant women

  2017cites this paper
• Cloning and expression of a cDNA coding for a human monocyte-derived plasminogen activator inhibitor (serine protease Inhibitor/urokinase/cDNA cloning/bacterial expression)

  2016cites this paper
• Plasmin-Antiplasmin System

  2016cites this paper
• CROSS-TALK BETWEEN THE PROTEOLYTIC AND NON-PROTEOLYTIC FUNCTIONS OF THE UROKINASE RECEPTOR

  2015influential citation
• The sGC activator inhibits the proliferation and migration, promotes the apoptosis of human pulmonary arterial smooth muscle cells via the up regulation of plasminogen activator inhibitor-2.

  2015cites this paper
• Characterisation of SerpinB2 as a stress response modulator

  2015cites this paper
• REGULATION OF ANTI-THROMBOGENETIC FACTORS IN ENDOTHELIUM

  2014cites this paper
• Forty years later and the role of plasminogen activator inhibitor type 2/SERPINB2 is still an enigma.

  2011cites this paper
• Forty Years Later and the Role of Plasminogen Activator Inhibitor Type 2/SERPINB2 Is Still an Enigma

  2011cites this paper
• Le TGF-[BETA] comme marqueur d'adhérences abdominales dans un modèle expérimental de poulain nouveau-né

  2009cites this paper
• The effect of severity of pre-eclampsia on the basal plate intervillous surface lining components : a confocal laser scanning microscopy study

  2009cites this paper
• [Clinical significance of the fibrinolysis system].

  2008cites this paper
• Concentrations of plasminogen activators and their inhibitors in blood preconceptionally, during and after pregnancy.

  2006cites this paper
• Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumor progression

  2005cites this paper
• Plasminogen activator inhibitor type 2 (PAI‐2) is present in normal human conjunctiva

  2005cites this paper
• Cloning and sequeaeing of cDNA for the rat plasmiuogen activator inhibitor

  2002cites this paper
• Levels of plasminogen activators and their inhibitors in maternal and umbilical cord plasma in severe preeclampsia.

  2002cites this paper
• The localization of the relaxed form of plasminogen activator inhibitor type 2 in human gingival tissues

  2001cites this paper
• Overexpression of plasminogen activator inhibitor type 2 in basal keratinocytes enhances papilloma formation in transgenic mice.

  2001cites this paper
• Placenta and Myometrium – The Two Main Sources of Fibrinolytic Components during Pregnancy

  2001cites this paper
• The Inhibitors of the Fibrinolytic System

  2001cites this paper
• Assessment of plasminogen activator inhibitor type 2 (PAI-2) as an imaging and therapeutic agent of human cancer

  2001cites this paper
• Nonenzymatic interactions between proteinases and the cell surface: novel roles in normal and malignant cell physiology.

  2000cites this paper
• Measuring plasminogen activator inhibitor activity in plasma by two enzymatic assays.

  2000cites this paper
• J. Perinat. Med. Coagulation and fibrinolysis in viable mid-trimester 27 (1999) 4582464 pregnancies of normal, intrauterine growth retardation, chromosomal anomalies and hydrops fetalis and their eventual obstetric outcome

  1999cites this paper
• Plasminogen activator inhibitor type 2 in human corneal epithelium.

  1999cites this paper
• Differential expression of plasminogen activators and their inhibitors in an organotypic skin coculture system

  1999cites this paper
• Plasminogenaktivatorinhibitor Typ 2: Biochemie, Molekularbiologie und Physiologie

  1999cites this paper
• Factors of the plasminogen activator system in human testis, as demonstrated by in-situ hybridization and immunohistochemistry.

  1999cites this paper
• PAI-2 inhibits the chemiluminescence of phagocytes and suppresses autoimmunity

  1999cites this paper
• Urokinase receptor cleavage and shedding : occurrence and consequences.

  1999cites this paper
• Difference in mRNA expression and occurrence of plasminogen activator inhibitors in intrauterine decidua of normal and ectopic human pregnancies.

  1999cites this paper
• Coagulation and fibrinolysis in viable mid-trimester pregnancies of normal, intrauterine growth retardation, chromosomal anomalies and hydrops fetalis and their eventual obstetric outcome

  1999cites this paper
• Preeclampsia: Haemostatic Status and the Short‐Term Effects of Methyldopa and Isradipine Therapy

  1998cites this paper
• Significance of the Plasminogen Activator Inhibitor of Placental Type (PAI-2) In Pregnancy

  1998cites this paper
• The Influence of Labor and Placental Separation on Hemostasis in Term Pregnancy

  1998cites this paper
• Localization and distribution of tissue type and urokinase type plasminogen activators and their inhibitors Type 1 and 2 in human and rhesus monkey fetal membranes.

  1998cites this paper
• Plasminogen activator inhibitor type-2. A spontaneously polymerizing serpin that exists in two topological forms.

  1997cites this paper
• Plasminogen Activator Inhibitor Type-2

  1997cites this paper
• Invasion of human glioma: role of extracellular matrix proteins.

  1996cites this paper
• The plasminogen activation system in tumour invasion and metastasis.

  1996cites this paper
• Plasminogen activators and inhibitors, D-dimer and β-TG in systemic lupus erythematosus pregnancy in relation to their obstetric outcome

  1996cites this paper
• Plasminogen activators and matrix metalloproteinases in angiogenesis.

  1996cites this paper
• Plasminogen activator inhibitor 2 in menstrual endometrium and in primary cultures of endometrial cells

  1996cites this paper
• Fibrinolysis during normal pregnancy and severe preeclampsia relationships between plasma levels of plasminogen activators and inhibitors.

  1996cites this paper
• Plasminogen activators and angiogenesis.

  1996cites this paper
• Intracellular Polymerization of the Serpin Plasminogen Activator Inhibitor Type 2 (*)

  1996cites this paper
• On the affinity between the plasminogen activator inhibitor type 2 and apolipoprotein A1.

  1996cites this paper
• Transcriptional Regulation of Tissue- and Urokinase-type Plasminogen Activator Genes by Thrombin in Human Fetal Lung Fibroblasts

  1995cites this paper
• Plasminogen activator inhibitor type 2: an intracellular keratinocyte differentiation product that is incorporated into the cornified envelope.

  1995cites this paper
• Biological and clinical aspects of plasminogen activator inhibitor type 2.

  1995cites this paper
• Diagnostic Efficacy of Plasma Urokinase-type Plasminogen Activator and Plasminogen Activator Inhibitor-2 in Differentiation of Hepatocellular Carcinoma from Cirrhosis

  1995cites this paper
• Partial characterization of novel serine proteinase inhibitors from human umbilical vein endothelial cells.

  1995cites this paper
• Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients.

  1994cites this paper
• Factors Involved In the Plasminogen Activation System in Human Breast Tumours

  1994cites this paper
• Immunohistochemical localization of urokinase‐type plasminogen activator and the plasminogen activator inhibitors 1 and 2 in early human implantation sites

  1994cites this paper
• Inhibition of tissue plasminogen activators and urokinase by human saliva.

  1994cites this paper
• Secretion of plasminogen activator inhibitor type 1 by cultured ovarian cells obtained from gonadotropin-treated immature rats.

  1994cites this paper
• Plasminogen activatior inhibitor type 1 in rat spermatozoa: localisation in the tail, in the acrosome and on the surface of the head

  1994cites this paper
• Receptor-Mediated Endocytosis of Plasminogen Activators

  1994cites this paper
• Plasminogen activators, plasminogen activator inhibitors and markers of intravascular coagulation in pre-eclampsia.

  1993cites this paper
• Plasminogen-activator inhibitor type 2 (PAI-2) is a spontaneously polymerising SERPIN. Biochemical characterisation of the recombinant intracellular and extracellular forms.

  1993cites this paper
• Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study.

  1993cites this paper
• New insights into the pathogenesis of coagulation dysfunction in acute promyelocytic leukemia.

  1993cites this paper
• Plasminogen activator inhibitor 2 reduces peritoneal fibrinolytic activity in inflammation

  1993cites this paper
• Biology and biochemistry of proteinases in tumor invasion.

  1993cites this paper
• Microglia express the type 2 plasminogen activator inhibitor in the brain of control subjects and patients with Alzheimer's disease.

  1993cites this paper
• Differential expression of plasminogen activators and their inhibitors in an organotypic skin coculture system.

  1993cites this paper
• Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas.

  1993cites this paper
• Plasminogen activators and inhibitors in normal late pregnancy, postpartum and in the postnatal period

  1992cites this paper
• Opposite and independent actions of cyclic AMP and transforming growth factor beta in the regulation of type 1 plasminogen activator inhibitor expression.

  1992cites this paper
• Mechanisms of fibrinolysis and clinical use of thrombolytic agents.

  1992cites this paper
• Binding Proteins of Protein Therapeutics

  1992cites this paper
• Expression of the urokinase receptor in vascular endothelial cells is stimulated by basic fibroblast growth factor

  1991cites this paper
• Dexamethasone and Phorbol Ester, but not Cytokines, Increase the Production of Plasminogen Activator Inhibitor Type-2 in the PL-21 Human Promyelocytic Leukemia Cell Line

  1991cites this paper
• The role of fibrinolytic factors in ischaemia

  1991cites this paper
• Identity between the placental protein PP10 and the specific plasminogen activator inhibitor of placental type PAI-2.

  1991cites this paper
• Perinatal Coagulation and Fibrinolysis

  1991cites this paper
• Perinatal Thrombosis and Hemostasis

  1991cites this paper
• The effects of metformin on the fibrinolytic system in diabetic and non-diabetic subjects.

  1991cites this paper
• Implantation, trophoblast differentiation and haemochorial placentation: mechanistic evidence in vivo and in vitro.

  1991cites this paper
• Plasminogen Activators in Endometrial Physiology and Embryo Implantation: A Review

  1991cites this paper
• Function of Receptor-Bound Urokinase

  1991cites this paper
• Tissue plasminogen activator and placental plasminogen activator inhibitor in human gingival fluid

  1991cites this paper
• Modulation of synovial fibroblast plasminogen activator and plasminogen activator inhibitor production by protein kinase C.

  1991cites this paper
• Plasminogen activator inhibitor-2 in patients with monocytic leukemia.

  1991cites this paper
• Study on the Source of Increased Plasminogen Activators (tPA, uPA) and their inhibitors (PAI-1, PAI-2) in Pregnancy Plasma

  1991cites this paper
• Purification and characterisation of plasminogen activator inhibitor 2 produced in Saccharomyces cerevisiae.

  1991cites this paper
• Concomitant Secretion by A431 Cells of Tissue Plasminogen Activator and a Specific Inhibitor Masks EGF Modulation of tPA Activity

  1990cites this paper
• Differential regulation of plasminogen activator and plasminogen activator inhibitor by osteotropic factors in primary cultures of mature osteoblasts and osteoblast precursors.

  1990cites this paper
• The haemostatic balance in groups of thrombosis-prone patients. With particular reference to fibrinolysis in patients with myocardial infarction.

  1990cites this paper
• Isolation of plasminogen activator inhibitor-2 (PAI-2) from human placenta. Evidence for vitronectin/PAI-2 complexes in human placenta extract.

  1990cites this paper
• Detection of cathepsin B, plasminogen activators and plasminogen activator inhibitor in human non-small lung cancer cell lines.

  1990cites this paper
• The Conformation Changes of the Finger Domain of Tissue Type Plasminogen Activator during the Activator-lnhibitor Reaction

  1990cites this paper
• Purification and characterization of recombinant plasminogen activator inhibitor-1 from Escherichia coli.

  1990cites this paper
• A Plasminogen Activator Inhibitor-2 from a Promyelocytic Leukemia Cell Line, PL-21, Binds to the Carboxy-Terminal Chain of Plasminogen Activators

  1990cites this paper
• Lysosomal degradation of receptor-bound urokinase-type plasminogen activator is enhanced by its inhibitors in human trophoblastic choriocarcinoma cells.

  1990cites this paper